Nrx pharmaceuticals, inc. (nasdaq: nrxp) announces completion of enrollment of its phase 2b/3 trial of nrx-101 in suicidal treatment resistant bipolar depression

Exceeded originally target enrollment (70) with n=74                        last patient, last visit expected in approximately six weeks; data to follow shortly thereafter positive data triggers milestone payment from alvogen, as previously announced. radnor, pa.
NRXP Ratings Summary
NRXP Quant Ranking